CPXX


Company Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced positive response rate results in AML patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented at the European Hematology …

Stock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Cancels Analyst and Investor Meeting and Postpones Annual Meeting of Stockholders

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that it is cancelling its Analyst and Investor meeting scheduled for Saturday, June 4, 2016 at 7:00 p.m.

Analysts Downgrade Two Volatile Healthcare Stocks: Celator Pharmaceuticals Inc (CPXX), StemCells Inc (STEM)

Healthcare analysts are weighing in today on leukemia drug maker Celator Pharmaceuticals Inc (NASDAQ:CPXX) and biotechnology company StemCells Inc (NASDAQ:STEM), as the stocks turned extremely volatile following acquisition …

Stock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc and Jazz Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share

Celator Pharmaceuticals Inc (NASDAQ:CPXX) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator …

Tuesday Morning’s Market Insights: Celator Pharmaceuticals Inc (CPXX), Intercept Pharmaceuticals Inc (ICPT), Amicus Therapeutics, Inc. (FOLD), Seadrill Ltd (SDRL)

Celator Pharmaceuticals Inc (NASDAQ:CPXX) is up an overwhelming 71% to $30.12 in pre-market trading following this morning’s announcement that the company will be …

Analysts Chime In On Two Rising Biotech Stocks: Celator Pharmaceuticals Inc (CPXX), Spark Therapeutics Inc (ONCE)

Celator Pharmaceuticals Inc Roth Capital analyst Joseph Pantginis weighs in today on Celator Pharmaceuticals Inc (NASDAQ:CPXX), after the biotech company announced that the FDA granted Breakthrough Therapy …

Stock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces VYXEOS™ Granted Breakthrough Therapy Designation

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation to VYXEOS (also known as CPX-351). VYXEOS …

Stock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces First Quarter 2016 Financial Results and Business Update

Celator Pharmaceuticals Inc (NASDAQ:CPXX) reported business highlights and financial results for the first quarter ended March 31, 2016. “The first quarter of 2016 was transformative …

Company Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOSTM Compared to Standard Treatment for Acute Myeloid Leukemia (AML)

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that patients treated in a Phase 2 clinical study with VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as …

Company Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces New Data for VYXEOS™ to be Presented at the American Association for Cancer Research Annual Meeting

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that data for VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351), its lead product candidate, will be presented …